Clinical Trial

Pharmacogenomics of Heparin-Induced Thrombocytopenia

Study acronym: PHIT
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated June 27, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT02717039
Lead Sponsor University of Arizona
Collaborators: American College of Clinical Pharmacy
Conditions Heparin-induced Thrombocytopenia
Enrollment 125 participants
Start Date 2016-03
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2024-06-27